Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Milciclib maleate - Nerviano Medical Sciences/Tiziana Life Sciences

Next Previous
X
Search
Drug Profile

Milciclib maleate - Nerviano Medical Sciences/Tiziana Life Sciences

Alternative Names: PHA 848125C; PHA-125; PHA-848125; PHA-848125AC; TZLS-201

Latest Information Update: 28 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; Tiziana Life Sciences
  • Class 3-ring heterocyclic compounds; Amides; Antineoplastics; Piperazines; Pyrazolones; Quinazolines; Small molecules
  • Mechanism of Action CDC2 protein kinase inhibitors; Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 5 inhibitors; Cyclin-dependent kinase-activating kinase inhibitors; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant thymoma; Thymic epithelial tumour
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Liver cancer; Malignant thymoma
  • Phase I/II Glioma
  • No development reported Malignant-mesothelioma; Solid tumours

Most Recent Events

  • 28 Jun 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Unknown (PO, Capsule)
  • 31 Dec 2023 Tiziana Life Sciences has patent protection for milciclib maleate worldwide, prior to December 2023
  • 31 Dec 2023 Tiziana Life Sciences has patents pending for milciclib maleate worldwide, prior to December 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top